diphtheria & tetanus toxoids/ acellular pertussis vaccine (Rx) - Infanrix, Tripedia, more..Daptacel
- Class: Vaccines, Combos
Adult Dosing & Uses
See tetanus & reduced diphtheria toxoids/ acellular pertussis vaccine (Tdap), or tetanus & diphtheria toxoids, adult (Td)
Pediatric Dosing & Uses
Dosing Forms & Strengths
diphtheria/tetanus/pertussis vaccine
vial
- 0.5mL
prefilled syringe
- 0.5mL
Acellular DTP (DTaP: Daptacel; Infanrix; Tripedia)
6 weeks-6 years
- 0.5 mL IM x 3 starting at 6-8 weeks q1-2Months; THEN 4th dose 6-12 months later & 5th dose at entry to school;
- For children <7 years old who didn't receive DTaP at early infancy, give first 3 doses q1Month, THEN 4th dose at least 6 months later
If >7 years old, use Tetanus & diphtheria toxoids, adult (Td)
If >10 years old, see tetanus & reduced diphtheria toxoids/ acellular pertussis vaccine (Tdap)
Drug Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
>10%
Inj site rxns
Headache
Drowsiness
Irritability
Anorexia
1-10%
Fever
Vomiting
Other Information
ADR's may be less with acellular pertussis vaccine
Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967
Contraindications & Cautions
Contraindications
Documented hypersensitivity
DTaP: >7 years or <6 weeks
History of Arthus reaction to prior tetanus vaccination (unless 10 yr have elapsed)
History of encephalopathy with pertussis-containing vaccine
Cautions
DTwP and Tri-Immunol: Contains detoxified diphtheria & tetanus toxins and whole-cell pertussis vaccine
DTaP (Tripedia) now contains <0.5 mcg thimerosal; Daptacel, Infanrix are thimerosal-free
Also available as DTwP with HIB (Tetramune)
Do not use DTaP with HIB (TriHIBit) for primary immunization of infants; only use for booster shots
Neurological disorder
History of Guillain-Barre syndrome with prior tetanus vaccine; weigh risk/benefit
Pregnancy & Lactation
Pregnancy Category: C
Lactation: excretion in milk unknown; use with caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Pharmacology
These products convey active immunity via stimulation of production of endogenously produced antibodies
The onset of protection from disease is relatively slow, but duration is long lasting (years)
Duration: >10 yr
Mechanism of Action
Production of specific antibodies
Print w/ Office Info
